Hengruiyuanzheng (Shenzhen) Biotechnology Co., Ltd.

The primary objective is to evaluate the effectiveness of MASCT-I combined with standard first-line chemotherapy with doxorubicin and ifosfamide in subjects with advanced soft tissue sarcoma. The secondary objective is to evaluate the safety and other efficacy indicators of MASCT-I combined with standard first-line chemotherapy with doxorubicin and ifosfamide in subjects with advanced soft tissue sarcoma.

The primary objective is to evaluate the improvement in PFS of MASCT-I+BSC maintenance therapy compared with single-collected PBMC cells+BSC in subjects with urothelial carcinoma who have achieved clinical benefits after standard first-line chemotherapy. The secondary objective is to evaluate other efficacy indicators of MASCT-I+BSC for maintenance therapy after standard first-line chemotherapy, and further evaluate the safety of MASCT-I in this population.

Primary objective: To investigate the safety and tolerability of MASCT-I in patients with solid tumors that have advanced metastatic or recurrent disease and have failed various standard treatments. Secondary objective: To investigate the immune response after administration of MASCT-I. Exploratory objective: To preliminarily explore the efficacy of MASCT-I.